(2,3-dimethoxyphenyl)-(1-(2-p-methoxyphenylethyl)-piperidin-4-yl)-methanol | 126405-25-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2,3-dimethoxyphenyl)-(1-(2-p-methoxyphenylethyl)-piperidin-4-yl)-methanol
• 英文别名: α-(2,3-dimethoxyphenyl)-1-[2-(4-methoxyphenyl)ethyl]-4-piperidine methanol；(2,3-Dimethoxyphenyl)(1-(4-methoxyphenethyl)piperidin-4-yl)methanol；(2,3-dimethoxyphenyl)-[1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl]methanol
• CAS: 126405-25-2
• 化学式: C₂₃H₃₁NO₄
• 分子量: 385.503
• InChiKey: ZLCFZMUGZLFBPL-UHFFFAOYSA-N

物化性质

• 沸点：
  526.9±50.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-甲氧基苯乙基溴 、 外消旋(2,3-二甲氧基苯基)- 在 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以26%的产率得到(2,3-dimethoxyphenyl)-(1-(2-p-methoxyphenylethyl)-piperidin-4-yl)-methanol
  参考文献：
  名称：

  Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET

  摘要：

  Radiolabelled piperidine derivatives such as [C-11] MDL 100907 and [F-18] altanserin have played an important role in diagnosing malfunction in the serotonergic neurotransmission. A variety of novel piperidine MDL 100907 derivatives, possible to label with F-18-fluorine, were synthesized to improve molecular imaging properties of [C-11] MDL 100907. Their in vitro affinities to a broad spectrum of neuroreceptors and their lipophilicities were determined and compared to the clinically used reference compounds MDL 100907 and altanserin. The novel compounds MA-1 (53) and (R)-MH.MZ (56) show K-i-values in the nanomolar range towards the 5-HT2A receptor and insignificant binding to other 5-HT receptor sub-types or receptors. Interestingly, compounds MA-1 (53), MH.MZ (55) and (R)-MH.MZ (56) provide a receptor selectivity pro. le similar to MDL 100907. These compounds could possibly be preferable antagonistic F-18-tracers for visualization of the 5-HT2A receptor status. Medium affine compounds (VK-1 (32), (51), (52), (54)) were synthesized and have K-i values between 30 and 120 nM. All promising compounds show logP values between 2 and 3, that is, within the range of those for the established radiotracers altanserin and MDL 100907. The novel compounds MA-1 (53) and (R)-MH.MZ (56) thus appear to be promising high affine and selective tracers of F-18-labelled analogues for 5-HT2A imaging with PET. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.03.021

文献信息

• Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
  申请人：Rao Srirama P.

  公开号：US20060069124A1

  公开（公告）日：2006-03-30

  Methods of modulating eosinophil migration, chemotaxis or generation, in vitro, ex vivo, and in vivo are provided. Methods include contacting eosinophils with an amount of 5-HT2A receptor agonist or antagonist sufficient to modulate eosinophil migration, chemotaxis or generation.

  提供了调节嗜酸性粒细胞在体外、体内和体内迁移、趋化或生成的方法。方法包括将嗜酸性粒细胞与足以调节嗜酸性粒细胞迁移、趋化或生成的5-HT2A受体激动剂或拮抗剂进行接触。
• N-Aralkyl piperidinemethanol derivatives
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0208235A1

  公开（公告）日：1987-01-14

  This invention relates to a new class of compounds having important biochemical and pharmacological properties. More particularly, this invention relates to N-aralkyl piperidinemethanol derivatives which are potent and selective inhibitors of the binding of serotonin at the 5HT2 receptor site, and to the processes for their preparation and use.

  本发明涉及一种具有重要生物化学和药理学性质的新类化合物。更具体地说，本发明涉及N-芳基烷基哌啶甲醇衍生物，它们是5HT2受体位点血清素结合的有效选择性抑制剂，并涉及其制备和使用的过程。
• Piperidinyl methanol derivatives for the treatment of anxiety
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0319962A2

  公开（公告）日：1989-06-14

  The present invention pertains to a method for the treatment of anxiety comprising administering a 1,4-­disubstituted piperidinyl methanol to a patient in need thereof.

  本发明涉及一种治疗焦虑症的方法，包括向有需要的患者施用 1,4-二取代哌啶甲醇。
• Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0337136A2

  公开（公告）日：1989-10-18

  The present invention pertains to the use of a class of serotonin 5HT₂ antagonists of the formula: wherein: each of R¹, R², R³, and R⁴ are independently selected from the group consisting of hydrogen, a C₁₋₆ alkyl group, halogen, trifluoromethyl, hydroxy, a C₁₋₆ alkoxy group, or an amino group; n is 2, 3, or 4; and the pharmaceutically acceptable acid addition salts thereof for the preparation of a pharmaceutical composition for the treatment of the extrapyramidal side effects associated with neuroleptic drug therapy.

  本发明涉及一类血清素 5HT₂ 拮抗剂的使用，其式如下： 其中： R¹、R²、R³和R⁴各自独立地选自由氢、C₁₋₆烷基、卤素、三氟甲基、羟基、C₁₋₆烷氧基或氨基组成的组；n为2、3或4；及其药学上可接受的酸加成盐，用于制备治疗与神经安定药物治疗相关的锥体外系副作用的药物组合物。
• 4-Piperidine methanol derivatives for the treatment of glaucoma
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0434021A2

  公开（公告）日：1991-06-26

  Use of a compound of the formula I: in which: each of R¹, R², R³, and R⁴ is independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, halogen, trifluoromethyl, hydroxy, C₁₋₆ alkoxy, or an amino group; n is 2, 3, or 4; and the pharmaceutically acceptable acid addition salts thereof for the preparation of a pharmaceutical composition for the treatment of glaucoma.

  使用式 I 的化合物 其中 R¹、R²、R³和R⁴各自独立地选自氢、C₁₋₆烷基、卤素、三氟甲基、羟基、C₁₋₆烷氧基或氨基组成的组；n为2、3或4；及其药学上可接受的酸加成盐，用于制备治疗青光眼的药物组合物。